BRIEF published on 01/26/2026 at 18:05, 10 days 10 hours ago ABIVAX: Share capital and voting rights as of December 31, 2025 Voting Rights Biotechnology Actions AMF Abivax
BRIEF published on 01/26/2026 at 18:05, 10 days 10 hours ago ABIVAX : Composition du capital social et droits de vote au 31 décembre 2025 Droits De Vote Biotechnologie Actions AMF Abivax
PRESS RELEASE published on 01/26/2026 at 18:00, 10 days 10 hours ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.12.25. ABIVAX annonce le nombre d'actions et de droits de vote au 31.12.25. Société de biotechnologie axée sur les traitements thérapeutiques dans les maladies inflammatoires chroniques Droits De Vote Biotechnologie Actions Abivax Maladies Inflammatoires
BRIEF published on 01/07/2026 at 22:10, 29 days 6 hours ago Abivax unveils its objectives for 2026 Abivax Obefazimod Phase 3 2026 RCH
BRIEF published on 01/07/2026 at 22:10, 29 days 6 hours ago Abivax dévoile ses objectifs pour 2026 Abivax Obefazimod Phase 3 2026 RCH
BRIEF published on 01/07/2026 at 22:10, 29 days 6 hours ago Abivax Reveals Strategic Plans for 2026 Regulatory Filing Abivax 2026 Outlook Ulcerative Colitis Market Obefazimod Trials Crohn’s Disease Research
BRIEF published on 01/07/2026 at 22:10, 29 days 6 hours ago Abivax dévoile ses plans stratégiques pour 2026 Dépôt Réglementaire Perspectives D'Abivax Pour 2026 Marché De La Colite Ulcéreuse Essais Cliniques Sur L'obefazimod Recherche Sur La Maladie De Crohn
PRESS RELEASE published on 01/07/2026 at 22:05, 29 days 6 hours ago Abivax présente ses perspectives pour 2026 Abivax présente ses perspectives pour 2026, annonçant des nouveautés dans le traitement de la rectocolite hémorragique, les progrès des essais ABTECT-UC et ENHANCE-CD, et l'avancement de son portefeuille de candidats médicaments Abivax Maladies Inflammatoires Chroniques Rectocolite Hémorragique Essais Cliniques Perspectives 2026
PRESS RELEASE published on 01/07/2026 at 22:05, 29 days 6 hours ago Abivax Provides 2026 Corporate Outlook Abivax provides 2026 corporate outlook, highlighting market insights, trial progress, and pipeline advancements in treating chronic inflammatory diseases like UC and CD Abivax Chronic Inflammatory Diseases 2026 Corporate Outlook UC CD
BRIEF published on 12/18/2025 at 22:10, 1 month 18 days ago Abivax joins the Nasdaq Biotechnology index Biotechnology Abivax Obefazimod Ulcerative Colitis Nasdaq Biotechnology
Published on 02/06/2026 at 03:50, 1 hour 7 minutes ago High Tide Resources annonce des placements privés sans courtier
Published on 02/06/2026 at 02:45, 2 hours 12 minutes ago High Tide Resources annonce des placements privés sans courtier
Published on 02/06/2026 at 00:57, 4 hours ago Noram Lithium Announces Closing of Fully Allocated Non-Brokered Financing
Published on 02/06/2026 at 00:00, 4 hours 57 minutes ago LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Published on 02/05/2026 at 23:15, 5 hours 42 minutes ago Amarc Further Expands Its Toodoggone Technical Team
Published on 02/05/2026 at 19:27, 9 hours 30 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/05/2026 at 18:46, 10 hours 11 minutes ago EQS-Adhoc: Mayr-Melnhof Karton AG: Impairment requirements impact profit for the financial year 2025
Published on 02/05/2026 at 18:09, 10 hours 48 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/05/2026 at 17:55, 11 hours 2 minutes ago Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
Published on 02/05/2026 at 17:40, 11 hours 17 minutes ago BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 01.02.26.
Published on 02/05/2026 at 19:15, 9 hours 42 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/05/2026 at 19:15, 9 hours 42 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES JANVIER 2026
Published on 02/05/2026 at 19:15, 9 hours 42 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
